Fosun Pharma
Fosun Pharma, officially known as Shanghai Fosun Pharmaceutical (Group) Co., Ltd., is a leading global healthcare company headquartered in China. Established in 1994, the firm has expanded its operations across major regions, including Asia, Europe, and North America, positioning itself as a key player in the pharmaceutical and healthcare industry. Fosun Pharma focuses on research and development, manufacturing, and distribution of innovative medicines, vaccines, and medical devices. Its core products, which include a diverse range of therapeutic solutions, are distinguished by their commitment to quality and efficacy. The company has achieved significant milestones, including strategic partnerships and acquisitions that enhance its market presence. With a strong emphasis on innovation and a robust pipeline, Fosun Pharma continues to solidify its position as a prominent force in the global healthcare landscape.
DitchCarbon Score
How does Fosun Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fosun Pharma's score of 27 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Fosun Pharma's reported carbon emissions
In 2023, Fosun Pharma reported total carbon emissions of approximately 960,864,000 kg CO2e. This figure includes 210,819,000 kg CO2e from Scope 1 emissions, 677,874,000 kg CO2e from Scope 2 emissions, and 72,171,000 kg CO2e from Scope 3 emissions. Over the years, the company has shown a trend of increasing emissions, with a notable rise from 949,469,000 kg CO2e in 2022 and 900,112,000 kg CO2e in 2021. Fosun Pharma has disclosed emissions data across all three scopes (1, 2, and 3) but has not set specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction targets suggests that while the company is tracking its emissions, it has yet to establish formal commitments to reduce its carbon footprint. Overall, Fosun Pharma's emissions reflect the challenges faced by the pharmaceutical industry in managing carbon outputs, particularly as they continue to grow in line with revenue increases. The company is headquartered in China (CN) and operates on a global scale, indicating the potential for significant impact through future climate action initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000 | 000,000 | 0,000,000 | 000,000 | 000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fosun Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
